Pirfenidone (AP01)

Small molecule

Phase 2Mechanism not established
Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Company guidance: topline data expected second half of 2027 (Avalyn Pharma Inc., 12 Aug 2026). “Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027” Source ↗

Company guidance: data expected second half of 2027 (Avalyn Pharma Inc., 12 Nov 2026). “Results from the MIST study of AP01, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF) are anticipated in the second half of 2027.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Other / comorbidity
NCT06951217 · Avalyn Pharma Inc.
2025-04-17 – 2031-12-31 · Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
What this study did
NCT06329401 · Avalyn Pharma Inc.
2024-04-03 – 2027-06 · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Hypersensitivity Pneumonitis, Interstitial Lung Disease With Systemic Sclerosis
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pirfenidone (AP01) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
Phase 2Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis …Active not recruiting
Est. primary completion 2027-06 · NCT06329401 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 2Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)Recruiting
Est. primary completion 2031-12-31 · NCT06951217 · CT.gov ↗
What to watch

See the full readout calendar ↗